Drug Profile


Alternative Names: Anti-CD19-CAR retroviral vector-transduced autologous T cells - University of Pennsylvania; Anti-CD19-CAR transduced T cells - Novartis/University of Pennsylvania; CART-019; CART-19; CART-19 cells; Chimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/Novartis; CTL 019; LG-740

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Lentigen Corporation; University of Pennsylvania
  • Developer Beijing Sanwater Biological Technology; Novartis; University of Pennsylvania
  • Class CAR-T cell therapies; Cell therapies; Gene therapies
  • Mechanism of Action CD19 antigen modulators; Gene transference; T lymphocyte replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Phase I B cell lymphoma; B cell prolymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma
  • Preclinical Breast cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 02 Mar 2017 Novartis initiates enrolment in a phase II trial for Acute lymphoblastic leukaemia (Second-line therapy or greater) in Austria (EudraCT2016-001991-31)
  • 13 Feb 2017 University of Pennsylvania terminates a phase II trial prior to enrolment for Acute lymphoblastic leukaemia (Second-line therapy or greater) in USA (NCT02167360)
  • 06 Dec 2016 Novartis plans to file an application with the European Medicines Agency in the EU for Acute lymphoblastic leukaemia in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top